Discover how US drugmaker Alnylam is transforming from a rare disease specialist into a major therapeutic platform company and why the Edinburgh Worldwide team remain confident in the significant long-term potential. Capital at risk.
Edinburgh Worldwide: stock spotlight on Alnylam
More Articles
-
Baillie Gifford US Growth Trust webinar
Baillie Gifford
11 February 2026
-
Scottish Mortgage Investor Webinar: Your Questions Answered
Baillie Gifford
10 February 2026
-
European Growth Trust: Manager Insights
Baillie Gifford
09 February 2026
-
Monks Q4 2025 investment update
Baillie Gifford
06 February 2026
-
Monks’ musings: the power of profit-driven performance
Baillie Gifford
03 February 2026
Editor's Picks
Loading...
